Literature DB >> 3100623

Identification of specific cytolytic immune responses against autologous tumor in humans bearing malignant melanoma.

L M Muul, P J Spiess, E P Director, S A Rosenberg.   

Abstract

Tumor-infiltrating lymphocytes from six patients with metastatic malignant melanoma were expanded by culture in recombinant interleukin 2. Three of the preparations were highly cytotoxic against autologous fresh melanoma tumor cells, but not against autologous fresh normal cells or allogeneic fresh tumor targets. The other three were highly cytotoxic against autologous fresh melanoma tumor cells and also had a limited capacity to kill allogeneic fresh tumor targets. The tumor-associated specific killer cells could be expanded from threefold to 95,652-fold with maintenance of specific antitumor lysis. The expanded tumor-infiltrating cells were Leu-4+ T cells, and in five of six patients the majority were Leu-3+. These studies demonstrate that the melanoma-bearing patient raises an immune response against autologous tumor and presents a method for the generation of human lymphocytes with antitumor reactivity that may be useful in the adoptive immunotherapy of tumors.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3100623

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  135 in total

Review 1.  Biological response modifiers in the management of patients with breast cancer.

Authors:  D L Longo; L C Hartmann
Journal:  Breast Cancer Res Treat       Date:  1990-09       Impact factor: 4.872

Review 2.  Role of major histocompatibility complex class-I molecules in tumor rejection. New insights from studies with synthetic peptides and transgenic mice.

Authors:  P Höglund; H G Ljunggren; K Kärre; G Jay
Journal:  Immunol Res       Date:  1990       Impact factor: 2.829

3.  Selection of cytotoxic T lymphocytes against autologous human melanoma from lymph nodes with metastatic melanoma using repeated in vitro sensitization.

Authors:  S P Leong; M E Granberry; Y M Zhou; T F Wang; T M Grogan
Journal:  Clin Exp Metastasis       Date:  1991 May-Jun       Impact factor: 5.150

4.  Modulation by IL-2 of CD70 and CD27 expression on CD8+ T cells: importance for the therapeutic effectiveness of cell transfer immunotherapy.

Authors:  Jianping Huang; Keith W Kerstann; Mojgan Ahmadzadeh; Yong F Li; Mona El-Gamil; Steven A Rosenberg; Paul F Robbins
Journal:  J Immunol       Date:  2006-06-15       Impact factor: 5.422

5.  Tumour infiltrating lymphocytes: insights into tumour immunology and potential therapeutic implications.

Authors:  K F Yoong; D H Adams
Journal:  Clin Mol Pathol       Date:  1996-10

6.  Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy.

Authors:  Steven A Rosenberg; James C Yang; Richard M Sherry; Udai S Kammula; Marybeth S Hughes; Giao Q Phan; Deborah E Citrin; Nicholas P Restifo; Paul F Robbins; John R Wunderlich; Kathleen E Morton; Carolyn M Laurencot; Seth M Steinberg; Donald E White; Mark E Dudley
Journal:  Clin Cancer Res       Date:  2011-04-15       Impact factor: 12.531

Review 7.  To affinity and beyond: harnessing the T cell receptor for cancer immunotherapy.

Authors:  Jessica E Thaxton; Zihai Li
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

8.  Characterization of interleukin-2-initiated versus OKT3-initiated human tumor-infiltrating lymphocytes from glioblastoma multiforme: growth characteristics, cytolytic activity, and cell phenotype.

Authors:  E A Grimm; J M Bruner; J Carinhas; J A Köppen; W G Loudon; L Owen-Schaub; P A Steck; R P Moser
Journal:  Cancer Immunol Immunother       Date:  1991       Impact factor: 6.968

Review 9.  Tumor-infiltrating lymphocytes for the treatment of metastatic cancer.

Authors:  M H Geukes Foppen; M Donia; I M Svane; J B A G Haanen
Journal:  Mol Oncol       Date:  2015-10-30       Impact factor: 6.603

10.  T cell recognition of melanoma antigens in association with HLA-A1 on allogeneic melanoma cells.

Authors:  Q Chen; M Smith; T Nguyen; D W Maher; P Hersey
Journal:  Cancer Immunol Immunother       Date:  1994-06       Impact factor: 6.968

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.